Insight Molecular Diagnostics Inc. (IMDX) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 7 recommend buying, 4 recommend holding, and 0 recommend selling.
The analyst consensus price target for IMDX is $10.50, representing a +207.0% upside from the current price of $3.42. Price targets range from a low of $9.00 to a high of $12.00.
